Adult urologyEffects of sildenafil citrate (viagra) on blood pressure in normotensive and hypertensive men
Section snippets
Material and methods
A SpaceLabs ambulatory BP monitor was used to record the systolic BP (SBP), diastolic BP (DBP), mean arterial pressure (MAP), and heart rate (HR). All data were recorded for later analysis.
The 49 men enrolled (22 hypertensive, 27 normotensive) were evaluated for 6 hours on 2 nights. On both nights, participants went to sleep at midnight and did not engage in sexual activity. No medication was taken on the first night; sildenafil 100 mg orally was taken at 9:00 pm on the other. The system was
Sample
The mean age of the 22 hypertensive men was 58.0 years, and the mean duration of hypertension was 7 years; normotensive men had a mean age of 42.3 years. The men with hypertension were treated with antihypertensive medications, including alpha-blockers (n = 10), calcium-channel antagonists (n = 8), and angiotensin-converting enzyme inhibitors (n = 7). Twelve of these men were taking only one drug; 10 were taking two or more medications. One of the hypertensive group also had angina. Preliminary
Comment
The results of our ambulatory monitoring indicate that a single oral 100-mg dose of sildenafil produces modest reductions in BP in both hypertensive and normotensive men, with no significant differences in the drug’s BP-lowering effects between these groups. BP was lowered to a statistically (but not clinically) significantly greater degree (P <0.05) in older men than in younger men, perhaps reflecting the higher baseline values in the older men. Note that the overall greater average age of the
Conclusions
Sildenafil causes small BP reductions in both normotensive and hypertensive men evaluated with ambulatory monitoring while active and at rest. This approach, which more closely approximates the actual clinical use of the drug than office measurements, confirms previous demonstrations of the safety of sildenafil. Overall, sildenafil’s effects in hypertensive men were not significantly greater than those in normotensive men. Concomitant use of one or more antihypertensive medications was not
References (30)
- et al.
Erectile dysfunction and coronary risk factorsprospective results from the Massachusetts Male Aging Study
Prev Med
(2000) - et al.
Sexual activity in hypertensive men treated with valsartan or carvedilola crossover study
Am J Hypertens
(2001) - et al.
Hypertension is associated with severe erectile dysfunction
J Urol
(2000) - et al.
Use of sildenafil (Viagra) in patients with cardiovascular disease
J Am Coll Cardiol
(1999) - et al.
Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy
Am J Hypertens
(2001) Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction
Clin Ther
(1998)- et al.
Management of sexual dysfunction in patients with cardiovascular diseaserecommendations of the Princeton Consensus Panel
Am J Cardiol
(2000) - et al.
Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure
J Am Coll Cardiol
(2000) Impotence
JAMA
(1993)- et al.
The impact of first-line antihypertensive drugs on erectile dysfunction
Pharmacotherapy
(1999)
Erectile dysfunction in general medicine practiceprevalence and clinical correlates
Int J Impot Res
A dose-escalation study to assess the efficacy and safety of sildenafil citrate in men with erectile dysfunction
BJU Int
Oral sildenafil in the treatment of erectile dysfunction
N Engl J Med
Sildenafil citrate (Viagra®) efficacy in the treatment of erectile dysfunction in patients with common concomitant conditions
Int J Clin Pract
Overall cardiovascular profile of sildenafil citrate
Am J Cardiol
Cited by (62)
Sildenafil: From angina to SARS-CoV-2
2021, SexologiesInfluence of Alcohol on Phosphodiesterase 5 inhibitors Use in Middle- to Old-Aged Men: A Comparative Study of Adverse Events
2019, Sexual MedicineCitation Excerpt :Furthermore, the inhibition of PDE-5 results in smooth muscle relaxation in the corpora cavernosa, as well as in the systemic vasculature, inducing subsequent vasodilation and decrease in BP.12–14 Thus, concomitant administration of PDE-5 inhibitor and alcohol may possibly induce clinically significant hemodynamic complications by further decreasing BP.13,15 Although some previous studies have evaluated the impact of PDE-5 inhibitor intake in combination with alcohol,15–17 there are no studies on the evaluation of the rate of concomitant use of alcohol and PDE-5 inhibitors among the general population.
The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade
2015, Drug Resistance UpdatesCitation Excerpt :Guggulsterone, resveratrol, sesamin, matairesinol, glycyrrhetinic acid, and ginsenosides are inhibitors of the ABCB1 transporter, but due to the lack of sufficient clinical studies, these compounds are not considered to be candidates for treatment of cancer (Kitagawa et al., 2007; Nabekura et al., 2005, 2008b, 2008c). Sildenafil is a selective PDE-5 inhibitor used to treat erectile dysfunction and pulmonary arterial hypertension (Vardi et al., 2002). Sildenafil inhibits the resistance caused by the overexpression of ABCB1 at 2.5, 5 and 10 μM in KB-C2 and KB-V1 cells, as well as ABCG2 at 10 and 50 μM in S1-M1-80, MCF-7/ADVP3000, MCF-7/Flv1000, HEK/ABCG2-G2, HEK/ABCG2-R5 and HEK/ABCG2-T7 (Shi et al., 2011).
Efficacy and Safety of Mirodenafil in Men Taking Antihypertensive Medications
2010, Journal of Sexual Medicine